Deutsche Bank Ag\ Neoleukin Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.92 - $2.25 $65,697 - $160,672	-71,410 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.72 - $5.23 $64,549 - $196,276	37,529 Added 110.77%	71,410 $134,000
Q4 2021 Feb 11, 2022	BUY	$4.65 - $7.75 $55,851 - $93,085	12,011 Added 54.92%	33,881 $163,000
Q3 2021 Nov 04, 2021	SELL	$6.05 - $9.66 $4,107 - $6,559	-679 Reduced 3.01%	21,870 $157,000
Q2 2021 Aug 11, 2021	BUY	$9.23 - $13.12 $563 - $800	61 Added 0.27%	22,549 $208,000
Q1 2021 May 13, 2021	SELL	$11.26 - $15.78 $21,957 - $30,771	-1,950 Reduced 7.98%	22,488 $276,000
Q4 2020 Feb 16, 2021	BUY	$10.17 - $14.56 $69,166 - $99,022	6,801 Added 38.56%	24,438 $345,000
Q3 2020 Nov 12, 2020	BUY	$9.68 - $17.01 $24,780 - $43,545	2,560 Added 16.98%	17,637 $212,000
Q2 2020 Aug 13, 2020	BUY	$9.95 - $17.05 $150,016 - $257,062	15,077 New	15,077 $250,000
Q4 2019 Feb 14, 2020	SELL	$2.65 - $12.72 $26,182 - $125,673	-9,880 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.33 - $3.76 $23,020 - $37,148	9,880 New	9,880 $28,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.